Montelukast: Indications, Dosing, and Monitoring
Montelukast is NOT a first-line agent for allergic rhinitis or asthma—intranasal corticosteroids are superior for rhinitis, and inhaled corticosteroids are preferred for asthma. However, montelukast serves as an alternative oral therapy when patients cannot or will not use inhaled/intranasal medications, or as add-on therapy in specific clinical scenarios.
Indications
Allergic Rhinitis
For seasonal allergic rhinitis: Montelukast is less effective than intranasal corticosteroids 1, 2. The 2017 Joint Task Force strongly recommends intranasal corticosteroids over leukotriene receptor antagonists for initial treatment in patients ≥15 years 1. The 2010 ARIA guidelines suggest oral antihistamines over montelukast due to better cost-effectiveness 3.
For persistent allergic rhinitis in adults: Guidelines conditionally recommend AGAINST using montelukast due to very limited efficacy and high cost 3.
When montelukast IS appropriate for rhinitis:
- Patients who refuse or cannot tolerate intranasal medications 1, 2
- Children with concomitant mild persistent asthma (treats both conditions) 2
- Preschool children with persistent allergic rhinitis (conditional recommendation) 3
- Parents who are "steroid-phobic" 2
- As combination therapy with antihistamines when intranasal corticosteroids fail 2
Asthma
For mild persistent asthma: Montelukast is an alternative to low-dose inhaled corticosteroids (Step 2 therapy) in patients unable or unwilling to use inhaled medications 4. However, inhaled corticosteroids remain the preferred first-line controller 4.
For moderate-to-severe persistent asthma: Montelukast can be added to inhaled corticosteroids as an alternative to long-acting beta-agonists (Steps 3-4), though this combination is less effective than inhaled corticosteroid + LABA 4.
Specific asthma scenarios where montelukast excels:
- Exercise-induced bronchoconstriction 5, 6
- Aspirin-exacerbated respiratory disease 6, 7
- Children with mild persistent asthma and coexisting allergic rhinitis 2
"Allergic Cough"
There is no evidence-based entity called "allergic cough" as a distinct diagnosis. If this represents:
- Cough-variant asthma: Treat as asthma (see above)
- Post-nasal drip from allergic rhinitis: Treat the rhinitis with intranasal corticosteroids first
- Upper airway cough syndrome: Montelukast has no established role
Dosing
Age-Based Dosing (FDA-Approved) 8, 9
Asthma and Seasonal Allergic Rhinitis:
- Adults and adolescents ≥15 years: 10 mg tablet once daily (evening preferred for asthma)
- Children 6-14 years: 5 mg chewable tablet once daily
- Children 2-5 years: 4 mg chewable tablet once daily
- Children 12-23 months (asthma only): 4 mg oral granules once daily
Perennial Allergic Rhinitis:
- Adults ≥15 years: 10 mg once daily
- Children 6-14 years: 5 mg once daily
- Children 2-5 years: 4 mg once daily
- Infants 6-23 months: 4 mg oral granules once daily
Timing: Evening dosing is traditional for asthma (based on circadian patterns of symptoms), but morning or evening dosing shows similar efficacy 8. Can be taken without regard to meals 8.
Onset of action: Begins by the second day of treatment; full benefit may take 2-4 weeks 2.
Monitoring Recommendations
Efficacy Monitoring
For asthma:
- Assess symptom control at 2-6 weeks 4
- Monitor FEV1 or peak flow if available
- Track rescue inhaler use (>2 days/week indicates inadequate control) 4
- Evaluate nocturnal awakenings
- If no improvement after 4-6 weeks, step up therapy or switch to inhaled corticosteroids
For allergic rhinitis:
- Assess nasal symptom scores at 2-4 weeks
- Evaluate quality of life impact
- If inadequate response, switch to intranasal corticosteroids (more effective) 1, 2
Safety Monitoring: CRITICAL
The FDA issued a Boxed Warning in March 2020 for neuropsychiatric adverse events 10, 7. This fundamentally changed montelukast's risk-benefit profile.
Mandatory pre-treatment counseling:
- Discuss risk of agitation, aggression, depression, sleep disturbances, suicidal thoughts/behavior
- Document this discussion in the medical record
- Provide written information to patients/families
Active monitoring during treatment:
- Screen for mood changes, behavioral changes, sleep disturbances at EVERY visit
- Specifically ask about: irritability, anxiety, depression, suicidal ideation, vivid dreams/nightmares
- Instruct patients/families to report ANY neuropsychiatric symptoms immediately
- Discontinue montelukast immediately if neuropsychiatric symptoms develop 7
Higher-risk populations requiring extra caution:
- Pre-existing psychiatric conditions
- History of depression or suicidal ideation
- Adolescents and young adults
- Consider alternative therapies in these patients 7
Other monitoring:
- No routine laboratory monitoring required 8
- Monitor for rare hepatotoxicity (transaminases if symptoms suggest liver dysfunction)
- Eosinophilia and vasculitis (Churg-Strauss syndrome) reported rarely—monitor if systemic symptoms develop
Common Pitfalls
Using montelukast as first-line for rhinitis: Always try intranasal corticosteroids first—they are significantly more effective 1, 2, 3
Expecting rapid symptom relief: Unlike antihistamines (work in 1 hour) or intranasal antihistamines (work in 15 minutes), montelukast takes 1-2 days minimum 2
Inadequate neuropsychiatric screening: The Boxed Warning is not theoretical—actively screen at every visit 10, 7
Using in moderate-to-severe asthma without inhaled corticosteroids: Montelukast should NEVER be monotherapy for moderate-to-severe asthma 4
Continuing despite lack of response: If no benefit after 4-6 weeks, switch to more effective therapy rather than continuing indefinitely
Ignoring drug interactions: Phenobarbital and rifampin reduce montelukast levels by 40%; consider dose adjustment or alternative therapy 8
Practical Algorithm for Montelukast Use
Consider montelukast when:
- Patient refuses/cannot use inhaled/intranasal medications, AND
- No history of psychiatric illness, AND
- Patient/family understands and accepts neuropsychiatric risks
Start therapy:
- Age-appropriate dose once daily
- Document neuropsychiatric counseling
- Schedule 2-4 week follow-up
At 2-4 weeks:
- Assess symptom improvement
- Screen for neuropsychiatric effects
- If inadequate response: switch to inhaled/intranasal corticosteroids
- If good response: continue with ongoing monitoring
Ongoing (every 3-6 months):
- Reassess need for continued therapy
- Screen for neuropsychiatric symptoms
- Consider step-down if symptoms well-controlled for 3+ months